Abstract 562P
Background
Existing literature supports the principle of early detection of colorectal cancer (CRC) via screening but has not definitively demonstrated an association between colonoscopy or polypectomy rates and CRC stage over time.
Methods
A longitudinal study was performed using the Australian national health database to obtain colonoscopy and polypectomy rates between 1998-2017. A second prospective database of CRC resection specimens was analysed for this period. The cohort was divided into three based on time intervals related to the national bowel cancer screening program: pre-commencement 1998-2006 (Period A), immediately post-commencement 2007-2011 (Period B), and subsequent years 2012-2017 (Period C).
Results
Annual colonoscopy rates doubled, and polypectomy rates tripled during the study (p<0.001). A total of 4506 patients underwent colorectal cancer resections. Annual colonoscopy rate correlated to a lower T-stage (p=0.038) and lower N-stage (p=0.026) leading to a 7% absolute (13.4% relative) increase in early CRC (stage I-II) in Period C (p<0.001). Across the study there was also a significant increase in right-sided tumours, and concurrent MMR deficiency and BRAF mutation.
Conclusions
Polypectomy and colonoscopy rates increased after the introduction of a national screening program which correlated to a clinically relevant shift to earlier CRC stages, a reduction in CRC incidence which manifested five years after implementation, and a reduced need for adjuvant chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10